These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 37150404)

  • 1. Tumor lysates-constructed hydrogel to potentiate tumor immunotherapy.
    Chen X; Jiang Z; Lin Y; Yu C; Nie X; Xu G; Xu W; Jiang Y; Luan Y
    J Control Release; 2023 Jun; 358():345-357. PubMed ID: 37150404
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Hydrogel-mediated tumor T cell infiltration and immune evasion to reinforce cancer immunotherapy.
    Xu G; Liu K; Chen X; Lin Y; Yu C; Nie X; He W; Karin N; Luan Y
    Nanoscale Horiz; 2024 Jan; 9(2):295-304. PubMed ID: 38086653
    [TBL] [Abstract][Full Text] [Related]  

  • 3. An injectable hydrogel using an immunomodulating gelator for amplified tumor immunotherapy by blocking the arginase pathway.
    Ren X; Wang N; Zhou Y; Song A; Jin G; Li Z; Luan Y
    Acta Biomater; 2021 Apr; 124():179-190. PubMed ID: 33524560
    [TBL] [Abstract][Full Text] [Related]  

  • 4. An Injectable Hydrogel to Modulate T Cells for Cancer Immunotherapy.
    Zhang D; Li Q; Chen X; Nie X; Xue F; Xu W; Luan Y
    Small; 2022 Aug; 18(32):e2202663. PubMed ID: 35843879
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Injectable microenvironment-responsive hydrogels with redox-activatable supramolecular prodrugs mediate ferroptosis-immunotherapy for postoperative tumor treatment.
    Cheng Z; Xue C; Liu M; Cheng Z; Tian G; Li M; Xue R; Yao X; Zhang Y; Luo Z
    Acta Biomater; 2023 Oct; 169():289-305. PubMed ID: 37544392
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Therapeutic supramolecular tubustecan hydrogel combined with checkpoint inhibitor elicits immunity to combat cancer.
    Wang F; Su H; Xu D; Monroe MK; Anderson CF; Zhang W; Oh R; Wang Z; Sun X; Wang H; Wan F; Cui H
    Biomaterials; 2021 Dec; 279():121182. PubMed ID: 34688987
    [TBL] [Abstract][Full Text] [Related]  

  • 7. CD4
    Xiao M; Xie L; Cao G; Lei S; Wang P; Wei Z; Luo Y; Fang J; Yang X; Huang Q; Xu L; Guo J; Wen S; Wang Z; Wu Q; Tang J; Wang L; Chen X; Chen C; Zhang Y; Yao W; Ye J; He R; Huang J; Ye L
    J Immunother Cancer; 2022 May; 10(5):. PubMed ID: 35580929
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Programming Injectable DNA Hydrogels Yields Tumor Microenvironment-Activatable and Immune-Instructive Depots for Augmented Chemo-Immunotherapy.
    Fan Y; Zhan M; Liang J; Yang X; Zhang B; Shi X; Hu Y
    Adv Sci (Weinh); 2023 Oct; 10(29):e2302119. PubMed ID: 37541435
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Functionalized biomimetic nanoparticles combining programmed death-1/programmed death-ligand 1 blockade with photothermal ablation for enhanced colorectal cancer immunotherapy.
    Xiao Y; Zhu T; Zeng Q; Tan Q; Jiang G; Huang X
    Acta Biomater; 2023 Feb; 157():451-466. PubMed ID: 36442821
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A prodrug hydrogel with tumor microenvironment and near-infrared light dual-responsive action for synergistic cancer immunotherapy.
    Ding M; Fan Y; Lv Y; Liu J; Yu N; Kong D; Sun H; Li J
    Acta Biomater; 2022 Sep; 149():334-346. PubMed ID: 35779775
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Targeting CAMKII to reprogram tumor-associated macrophages and inhibit tumor cells for cancer immunotherapy with an injectable hybrid peptide hydrogel.
    Dai X; Meng J; Deng S; Zhang L; Wan C; Lu L; Huang J; Hu Y; Zhang Z; Li Y; Lovell JF; Wu G; Yang K; Jin H
    Theranostics; 2020; 10(7):3049-3063. PubMed ID: 32194854
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A Polymeric Hydrogel to Eliminate Programmed Death-Ligand 1 for Enhanced Tumor Radio-Immunotherapy.
    Shen W; Pei P; Zhang C; Li J; Han X; Liu T; Shi X; Su Z; Han G; Hu L; Yang K
    ACS Nano; 2023 Dec; 17(23):23998-24011. PubMed ID: 37988029
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Tumors attenuating the mitochondrial activity in T cells escape from PD-1 blockade therapy.
    Kumar A; Chamoto K; Chowdhury PS; Honjo T
    Elife; 2020 Mar; 9():. PubMed ID: 32122466
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Molecular heterogeneity of anti-PD-1/PD-L1 immunotherapy efficacy is correlated with tumor immune microenvironment in East Asian patients with non-small cell lung cancer.
    Jin R; Liu C; Zheng S; Wang X; Feng X; Li H; Sun N; He J
    Cancer Biol Med; 2020 Aug; 17(3):768-781. PubMed ID: 32944405
    [No Abstract]   [Full Text] [Related]  

  • 15. Injectable polypeptide hydrogel-based co-delivery of vaccine and immune checkpoint inhibitors improves tumor immunotherapy.
    Song H; Yang P; Huang P; Zhang C; Kong D; Wang W
    Theranostics; 2019; 9(8):2299-2314. PubMed ID: 31149045
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Managing Hyperprogressive Disease in the Era of Programmed Cell Death Protein 1/Programmed Death-Ligand 1 Blockade: A Case Discussion and Review of the Literature.
    Grecea M; Marabelle A; Ammari S; Massard C; Champiat S
    Oncologist; 2020 May; 25(5):369-374. PubMed ID: 32091646
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Combination cancer immunotherapy targeting TNFR2 and PD-1/PD-L1 signaling reduces immunosuppressive effects in the microenvironment of pancreatic tumors.
    Zhang X; Lao M; Xu J; Duan Y; Yang H; Li M; Ying H; He L; Sun K; Guo C; Chen W; Jiang H; Zhang X; Bai X; Liang T
    J Immunother Cancer; 2022 Mar; 10(3):. PubMed ID: 35260434
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The Tumor Microenvironment Regulates Sensitivity of Murine Lung Tumors to PD-1/PD-L1 Antibody Blockade.
    Li HY; McSharry M; Bullock B; Nguyen TT; Kwak J; Poczobutt JM; Sippel TR; Heasley LE; Weiser-Evans MC; Clambey ET; Nemenoff RA
    Cancer Immunol Res; 2017 Sep; 5(9):767-777. PubMed ID: 28819064
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A single-shot prophylactic tumor vaccine enabled by an injectable biomembrane hydrogel.
    Nie X; Shi C; Chen X; Yu C; Jiang Z; Xu G; Lin Y; Tang M; Luan Y
    Acta Biomater; 2023 Oct; 169():306-316. PubMed ID: 37574158
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comprehensive insights into the effects and regulatory mechanisms of immune cells expressing programmed death-1/programmed death ligand 1 in solid tumors.
    Liu M; Sun Q; Wei F; Ren X
    Cancer Biol Med; 2020 Aug; 17(3):626-639. PubMed ID: 32944395
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.